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Abstract There has been increasing interest in noninva-
sive methods of assessing liver ﬁbrosis over the last dec-
ade. The use of transient elastography in measuring liver
stiffness has become the forefront of a wide range of
noninvasive tools. Most of the other methods are based on
measurements of biomarkers associated with ﬁbrosis.
There are several reasons for its wide acceptance, including
the ease of performing a scan, the short procedure time, the
results being immediately available on completion of the
examination, and its reproducibility. For chronic hepatitis
B (CHB), the cut-off values for F3 and F4 ﬁbrosis range
between 7.5–12.0 and 11.0–13.4 kPa, respectively,
although the cut-offs may be slightly lower in those with
normal ALT. In addition to measuring liver ﬁbrosis, recent
studies have demonstrated several other roles for transient
elastography, including selecting patients who will beneﬁt
from antiviral therapy, monitoring response to antiviral
therapy, and predicting long-term outcomes. However,
there are limitations associated with transient elastography,
including the confounding effects of inﬂammatory activity,
and to a lesser extent, steatosis, on liver stiffness. There is
also reduced accuracy observed in lower ﬁbrosis stages
(F0–F2). Furthermore, the incidences of failed and unreli-
able scan have been reported to be * 3 and 16%,
respectively. Although liver biopsy can be avoided in an
estimated 50–60% using transient elastography, in situa-
tions where liver stiffness measurement is nondiagnostic or
inconsistent with the clinical picture, a biopsy is still rec-
ommended. Further studies are needed to consolidate the
role of transient elastography in the management of CHB,
and for incorporation of this method into current treatment
guidelines.
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Introduction
An estimated 400 million people worldwide are chronically
infected with the hepatitis B virus (HBV), with the
majority located in the Asia Paciﬁc and sub-Saharan
region. HBV infection constitutes a signiﬁcant health
burden, with up to 40% chronically infected patients
developing complications of liver disease, including cir-
rhosis and hepatocellular carcinoma (HCC) [1, 2]. In
patients with chronic hepatitis B (CHB) infection, deter-
mination of the severity of liver ﬁbrosis is particularly
important for several reasons. First, the degree of ﬁbrosis
has prognostic signiﬁcance. Second, it helps to identify
patients who are likely to have the most beneﬁt from
antiviral therapy. Third, for those patients who are already
receiving treatment, assessment of liver ﬁbrosis may be
helpful in determining their response to therapy. Finally,
HCC and variceal screening should be implemented for
patients identiﬁed with cirrhosis.
Currently, percutaneous liver biopsy is the most com-
monly used method for assessing liver ﬁbrosis, and remains
the gold standard, despite the limitations associated with
inadequate specimen size and sampling error [3, 4]. The
interpretation of liver histology is also subjected to both
intra- and inter-observer variability, leading to erroneous
staging of ﬁbrosis. In addition, liver biopsy is an invasive
procedure which can be associated with signiﬁcant mor-
bidity (and occasional mortality), rendering it less
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strongest driving factor for the development of noninvasive
methods to assess liver ﬁbrosis.
Transient elastography using Fibroscan (Echosens,
Paris, France) is now available in many countries since its
development in 2003, and has become one of the leading
noninvasive methods to determine liver ﬁbrosis. The
measurement of liver stiffness is based on the principle that
an increase in liver ﬁbrosis is proportional to a higher liver
stiffness. The Fibroscan consists of a probe with an ultra-
sound transducer mounted on the axis of a vibrating piston.
A piston is used to create a mechanical wave of low fre-
quency and amplitude, creating a shear wave that is
propagated through the liver tissue. The ultrasound trans-
ducer, which is located at the tip of the probe, is then used
to map out the mechanical perturbation that was induced by
the vibrating piston. The velocity of the shear wave can
then be calculated, with higher shear wave velocity cor-
responding to higher liver stiffness, which corresponds to a
higher stage of ﬁbrosis. The liver stiffness value obtained
from transient elastography ranges from a minimum of
2.5 kPa to a maximum reading of 75.0 kPa.
The popularity of transient elastography stems not only
from its noninvasive nature and the absence of adverse
effects, but also from the fact that the investigation can be
rapidly performed, with an average procedure time of
*5 min. Furthermore, the results are immediately available
at the time of completion of the examination. Another
advantage is that transient elastography can be easily
learned within a short training period with highly repro-
ducible results [8]. The current review will focus on the role
of transient elastography in patients with CHB, highlighting
the current and potential clinical applications and the lim-
itations associated with liver stiffness measurement (LSM).
Assessment of liver ﬁbrosis
The current primary indication for performing transient
elastography is for the assessment of liver ﬁbrosis to guide
the treatment decisions. Most of the initial studies on LSMs
have been performed in Caucasian patients with chronic
hepatitis C, and there are abundant data validating the
accuracy of transient elastography in this setting [9–11].
Since then, there have been many studies on the use of LSM
in other liver diseases, including primary biliary cirrhosis,
nonalcoholic fatty liver disease, and CHB [12–16]. Several
meta-analyses performed recently have conﬁrmed the
accuracy of LSM in predicting signiﬁcant liver ﬁbrosis [17,
18]. In a meta-analysis of 50 studies, the mean area under
receiver operating characteristics curve (AUROC) for the
diagnosis of signiﬁcant ﬁbrosis, severe ﬁbrosis, and cir-
rhosis was 0.84, 0.89, and 0.94, respectively [17].
One of the important aspects of interpreting liver stiff-
ness results is the cut-off values that are adopted for the
different stages of ﬁbrosis, with higher cut-off levels cor-
responding to a higher ﬁbrosis stage. These cut-off values
have been derived from individual validation studies, and
therefore are dependent on the population of patients that
were recruited for those studies. Furthermore, the cut-off
values are disease speciﬁc, with different values used for
different disease etiologies. It is therefore important to
adopt the values that are relevant to the disease and ethnic
group as there are considerable differences. The reason for
the difference in cut-off values between different diseases
is not known, although the distribution of ﬁbrous material
is dependent on the origin of liver injury, which in turn is
dependent on the underlying pathology. For example, the
cirrhosis arising from CHB is often macronodular, and the
pattern of nodule distribution and ﬁbrous deposition may
affect the liver stiffness. Another example is the centri-
zonal ﬁbrosis of alcoholic liver disease, resulting in
micronodular cirrhosis.
Validation studies in CHB
In an early validation study of 173 patients with CHB from
ﬁve French hospitals, the performance of transient elas-
tography was shown to be comparable with the results
observed in patients with chronic hepatitis C. The AUROC
for F C2, F C3, and F = 4 were 0.81, 0.93, and 0.93,
respectively, with optimal cut-off liver stiffness values of
7.2, 8.1, and 11.0 kPa, respectively [15]. A similar cut-off
value of 10.3 kPa for cirrhosis was obtained from a Korean
study [19]. In another study of 161 Chinese patients with
CHB from Hong Kong, the AUROC for F C3 and F = 4
were 0.87 and 0.93, with an optimal cut-off value of
9.0 kPa for diagnosing liver cirrhosis [16]. Those with
elevated alanine aminotransferase (ALT) had higher opti-
mal cut-off levels compared to those with normal levels. A
study of 188 CHB patients from Italy identiﬁed an optimal
cut-off value of 7.5 and 11.8 kPa for S C3 and cirrhosis,
respectively [20]. The optimal cut-off values for signiﬁcant
ﬁbrosis and cirrhosis in patients with CHB are summarized
in Table 1.
However, there are limitations associated with valida-
tion studies. Although liver biopsy is the current ‘‘gold’’
standard for assessing liver ﬁbrosis, it is an imperfect
benchmark. Sampling error remains one of the important
limitations of liver biopsy, with size, length, and number of
samples obtained being contributing factors. Therefore
validation studies using liver biopsy as a reference will
also be subjected to these limitations. Other factors which
may affect the accuracy of validation studies include
the unequal distribution of ﬁbrosis stages in the study
cohorts, the lack of concurrent biopsies and liver stiffness
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biopsy specimens.
Normal liver stiffness
In addition to diagnosing patients with signiﬁcant ﬁbrosis
and cirrhosis, it is also important to identify patients with
normal liver or those with minimal ﬁbrosis by having a
cut-off value which deﬁnes normal liver stiffness. In a
study of 429 healthy subjects, the mean liver stiffness was
5.49 ± 1.59 kPa, with slightly higher values in males
compared with females (5.81 vs. 5.32 kPa, respectively,
p = 0.0002) and in subjects with higher body mass index
(BMI) [30 compared with BMI B30 (6.26 vs. 5.33 kPa,
respectively, p \0.0001) [21]. A mean liver stiffness of
4.8 ± 1.3 kPa was described in another study of 152
normal subjects from Romania, with a lower value
observed in females compared with males (4.6 vs.
5.1 kPa, respectively, p = 0.0082) [22]. In a study of 602
blood donors from Italy, the median liver stiffness was
4.4 kPa [23]. The normal liver stiffness in Asian subjects
appears to be comparable. A study of 69 healthy living
liver and kidney donors admitted for transplantation in
Korea showed a liver stiffness range of 3.9–5.3 kPa [24].
In another study of 28 Chinese living liver donors, the
median liver stiffness was 4.6 kPa with all subjects hav-
ing values of \7.2 kPa [25]. This cut-off value is lower
than the cut-off value used for signiﬁcant ﬁbrosis without
an overlap.
Indications for transient elastography in CHB
Apart from the assessment of liver ﬁbrosis, LSM may also
have other clinical applications. In patients with CHB,
transient elastography may be helpful in selecting patients
for antiviral therapy and predicting outcome of HBV
infection.
Determining the phase of infection
The natural history of CHB infection can be described in
four phases, namely the immunotolerant phase, immune
clearance phase, quiescent phase, and the reactivation
phase [26]. The clinical relevance of the different phases is
predominantly to determine whether there is underlying
signiﬁcant disease activity to warrant antiviral therapy.
For hepatitis B e-antigen (HBeAg)-positive patients, it is
important to identify those who are in the immune-clear-
ance phase so that antiviral therapy can be considered for
those with signiﬁcant disease activity. At present there is
no reliable marker to accurately indicate the transition from
immunotolerance to the immune clearance phase. The
HBV DNA levels are not useful in HBeAg-positive
patients as patients in the immune tolerant phase have very
high viral load, but have minimal or absent disease activity
[27]. Although higher ALT levels have shown to be asso-
ciated with increased risk of ﬁbrosis and cirrhosis [28, 29],
using ALT as a surrogate marker for transition into
the immune clearance phase may not be reliable as a
Table 1 Optimal cut-off levels
of signiﬁcant ﬁbrosis ( F C 2/
S C 3) and cirrhosis in patients
with CHB
PPV positive predicitive value,
NPV negative predictive value,
LR (?) positive likelihood ratio,
LR (-) negative likelihood ratio
Parameters Marcellin et al. [15] Oliveri et al. [20] Chan et al. [16] Kim et al. [19]
Normal ALT High ALT
Number 173 188 58 98 91
Ethnicity French Italian Chinese Chinese Korean
F C 2/S C 3
Cut-off (kPa) 7.2 7.5 – – –
Sensitivity 70 93 – – –
Speciﬁcity 83 83 – – –
PPV 80 77 – – –
NPV 73 97 – – –
LR (?) 4.1 8.2 – – –
LR (-) 0.36 0.07 – – –
Cirrhosis
Cut-off 11.0 11.8 9.0 13.4 10.3
Sensitivity 93 86 100 75 59
Speciﬁcity 87 96 88 93 78
PPV 38 87 75 78 68
NPV 99 96 100 92 72
LR (?) 7.1 23.1 8.6 11.1 2.7
LR (-) 0.08 0.14 0 0.27 0.53
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activity have normal ALT levels [28, 30–32]. Transient
elastography has a potential role not only in identifying
patients in the ‘‘immune clearance phase’’ with normal
ALT, but also in identifying those with elevated liver
stiffness, which may indicate underlying disease activity or
established ﬁbrosis. Studies are required to determine the
usefulness of LSM in this unexplored role.
For HBeAg-negative patients, various studies have
shown that multiple factors including older age, low platelet
count, male gender, and higher ALT levels are associated
with increased severity of ﬁbrosis [28, 29, 33–36]. Transient
elastography may also have a role in distinguishing patients
who are inactive carriers from those who have ongoing
disease activity. In a study of 220 HBeAg-negative CHB
patients, of which 95 had persistent or intermittent elevation
of ALT and/or HBV DNA [10
5 copies/mL, there was a
signiﬁcantly higher mean liver stiffness compared to those
who were inactive carriers (8.53 vs. 4.83 kPa, respectively,
p \0.001) [37]. A study of 68 inactive carriers showed a
mean liver stiffness value of 5.0 kPa [20]. In another recent
study of 329 HBeAg-negative patients, the liver stiffness
was signiﬁcantly lower in inactive carriers compared to
those with active hepatitis (4.8 vs. 6.8 kPa, p\0.0001) [38].
A cut-off value of 5.0 kPa may be useful in HBeAg-nega-
tive patients to identify those with underlying activity or
signiﬁcant ﬁbrosis despite having ALT levels within the
normal ranges.
Selection of patients for antiviral therapy
In CHB, transient elastography is likely to be most useful
in situations where liver biopsy is recommended and
measuring liver stiffness can obviate the need for an
invasive procedure. In the current Asia-Paciﬁc consensus
statement and the American Association for the Study of
Liver Diseases (AASLD) guidelines on the management of
CHB, liver biopsy is recommended for patients aged
[40 years with ALT \29 upper limit of normal (ULN)
and HBV DNA [20,000 IU/mL (for HBeAg-positive
patients) or [2,000 IU/mL (for HBeAg-negative patients)
[39, 40]. Those patients with signiﬁcant ﬁbrosis would be
candidates for antiviral therapy. It has not been well doc-
umented how many patients with ALT levels between 0.5
and 29 ULN have signiﬁcant ﬁbrosis/cirrhosis. Identiﬁ-
cation of these patients is important not only for antiviral
treatment, but also for the implementation of variceal and
HCC screening.
Monitoring response to antiviral therapy
For patients already on antiviral therapy, transient elas-
tography may have a potential role in monitoring disease
response to treatment, and to assess the regression of liver
ﬁbrosis. Previous studies have demonstrated the reversal of
ﬁbrosis in CHB patients receiving long-term antiviral
therapy [41, 42]. However, apart from clinical trial settings,
the on-treatment assessment of ﬁbrosis using repeated liver
biopsies is usually not practicable. In a study of 20 patients
who were commenced on entecavir therapy, the median
liver stiffness decreased from 11.2 to 7.8 kPa (p = 0.009)
[43]. In another study of 58 Chinese patients with CHB and
elevation of ALT from 1 to 109 ULN, there was a sig-
niﬁcantly lower median liver stiffness after commencement
of antiviral therapy with normalization of ALT compared
to pretreatment levels (6.4 vs. 7.9 kPa, respectively,
p \0.001). Despite these encouraging results, the use of
transient elastography in this setting is confounded by the
effect of ALT and inﬂammation on liver stiffness. The
decline in liver stiffness may be due to the decline in
inﬂammatory activity rather than a true improvement in
ﬁbrosis, and further studies with paired liver stiffness and
histological data are needed to answer this uncertainty. It
would be more informative for treatment response to have
serial LSMs after normalization of ALT in the course of
long-term treatment. Performing repeated measurements at
close interval is unlikely to be of beneﬁt, as ﬁbrosis
regression is unlikely to be reﬂected over short periods.
Disease prognosis
As transient elastography is a relatively new technology,
studies on the usefulness of LSM in predicting long-term
outcomes including HCC and liver-related mortality are
limited. In a large prospective study of more than 800
patients with chronic hepatitis C followed up for a mean
period of 3 years, liver stiffness was an independent pre-
dictor of subsequent development of HCC [44]. Similar
results were also demonstrated for patients with CHB. In
HBeAg-negative CHB patients followed up for a median
length of 35 months, those with liver stiffness C10 kPa had
a higher cumulative incidence of HCC (9 vs. 0%, respec-
tively, p \0.001) and liver-related mortality (4 vs. 0%,
respectively, p\0.001) compared to those who had lower
stiffness scores [45]. Another recent study of 1,130 CHB
patients showed that in addition to older age, male gender,
and heavy alcohol intake, a LSM of[8 kPa was associated
with a signiﬁcant risk of developing HCC [46]. Moreover,
there was an increase in hazard ratio with increasing gra-
dient of liver stiffness, from 3.07, 4.68, 5.55, and 6.6 for
liver stiffness 8.1–13, 13.1–18, 18.1–23, and[23 kPa,
respectively. The results of these studies demonstrate that
transient elastography can be useful as a screening tool to
risk stratify CHB patients so that HCC screening and close
monitoring can be implemented for those in the high-risk
group.
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that the degree of liver stiffness elevation may be predictive
of underlying cirrhotic complications. Correlation between
liver stiffness and the presence of esophageal varices has
been reported in several studies predominantly involving
chronic hepatitis C patients [47–50]. However, not all
studies have shown correlation between liver stiffness and
variceal size. Furthermore, the cut-off liver stiffness values
for the prediction of large (grade C2) varices in these
studies were variable with suboptimal speciﬁcity. This may
be explained by the fact that variceal size is dependent on
the degree of portal hypertension, which is not directly
related to the severity of the cirrhosis. The use of transient
elastography is currently insufﬁcient to predict the presence
or absence of varices in CHB patients with cirrhosis, and
upper endoscopy screening is still recommended.
Effects of inﬂammation on liver stiffness
Now there is unequivocal evidence showing that liver
stiffness can be affected by the degree of underlying liver
inﬂammatory activity. One of the earliest evidences sug-
gesting that inﬂammation can increase liver stiffness values
was from a large population study of 1,196 Chinese
patients with CHB, showing a positive correlation with
ALT levels and LSMs [51]. Subsequent studies showed
that severe ﬂares of hepatitis may reduce the accuracy of
transient elastography in determining liver ﬁbrosis [52–55].
In a study of patients with severe ﬂares of hepatitis B
(deﬁned as ALT[109 ULN) followed up prospectively
for 1 year, there was a signiﬁcant decline of liver stiffness
from the time of severe ﬂare, at 3–6 months, and at
12 months (16.8 vs. 7.9 vs. 6.9 kPa, respectively, all
p\0.05) [56]. In fact, a subgroup of patients underwent
repeat elastography 4 weeks from the time of ﬂare, and a
signiﬁcant decline in liver stiffness was already evident at
that early time point. The liver stiffness score was much
higher than the expected value for the stage of ﬁbrosis
observed on liver histology. This suggests that the increase
in liver stiffness was likely attributed to the inﬂammatory
inﬁltration rather than actual ﬁbrosis or cirrhosis.
It is likely that even lesser degrees of liver inﬂammation
can affect LSM in patients with CHB. This was suggested
by an earlier study showing a gradient of liver stiffness in
patients with ALT\0.59 ULN, 0.5–19 ULN, 1–29 ULN,
and 2–59 ULN (5.6, 6.5, 8.3, and 10.6 kPa, respectively,
all p\0.001) [51]. A recent study of 58 CHB patients with
ALT 1–109 ULN who achieved normalization of ALT
with a median time of 3 months after commencing oral
antiviral therapy showed a signiﬁcant lower median liver
stiffness compared to the baseline measurements (6.4 vs.
7.9 kPa, respectively, p\0.001) [57]. The AUROC curve
for diagnosing F2 ﬁbrosis in patients with elevated ALT
was 0.68 compared with 0.73 after ALT normalization,
suggesting a lower diagnostic accuracy of transient elas-
tography in subjects with elevated ALT levels [57].
Effects of steatosis on liver stiffness
The concurrent existence of metabolic syndrome or hepatic
steatosis in CHB patients may increase the risk of ﬁbrosis
and cirrhosis. In a study of 1,466 patients with CHB,
metabolic syndrome was found to be an independent risk
factor for advanced liver ﬁbrosis [58]. Metabolic syndrome
and steatosis may also affect liver stiffness. In a study of
429 healthy subjects without known liver disease, liver
stiffness was found to be signiﬁcantly higher in those with
metabolic syndrome compared to those without (6.51 vs.
5.33 kPa, respectively, p\0.0001) [21]. It remains a pos-
sibility that fat within hepatocytes may alter the propaga-
tion time of the shear wave through the liver, thereby
affecting the liver stiffness values. The diagnostic accuracy
of transient elastography appears to be preserved in Asian
subjects with nonalcoholic fatty liver disease [14, 59],
although it was shown in a recent study to be reduced in
European subjects [60].
Diagnostic models and algorithms
Several models have been developed to further improve the
diagnostic accuracy of transient elastography in patients
with CHB. To take into the account the effect of elevated
ALT as described previously, an algorithm using different
liver stiffness cut-off values was derived for normal and
elevated ALT levels (deﬁned as[1–59 ULN) to diagnose
bridging ﬁbrosis ([9.0–12.0 kPa and[12.0 kPa, respec-
tively) and cirrhosis ([12.0 and [13.4 kPa, respectively)
[16]. Based on this model, an estimated 62 and 58% of
patients with normal and elevated ALT, respectively, could
avoid a liver biopsy.
Other studies have looked at combining transient elas-
tography with another noninvasive modality using bio-
chemical markers to improve the diagnostic accuracy.
Combining the use of transient elastography and Forns
index (using platelet count, GGT, age, and cholesterol) was
shown to improve the speciﬁcity of diagnosing advanced
ﬁbrosis from 87 to 98% in a validation cohort of 82 CHB
patients [61]. In another study of 330 CHB patients, the use
of liver stiffness and spleen diameter to platelet ratio index
(LSPRI) improved the AUROC for diagnosing cirrhosis
from 0.919 for liver stiffness alone to 0.956 when com-
bined with spleen diameter and platelet levels (p = 0.032)
[62]. The use of less commonly available biomarkers
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macroglobulin levels to construct a scoring index (the
HALF index) was shown to have a signiﬁcantly higher
AUROC for predicting signiﬁcant ﬁbrosis compared with
transient elastography alone (0.915 vs. 0.877, respectively,
p = 0.01) [63].
Discordant results
In addition to inﬂammatory activity within the liver, other
factors may cause discordant results between transient
elastography and liver biopsy staging of ﬁbrosis. In a study
of 251 patients with chronic liver disease from viral hep-
atitis B and C and nonalcoholic steatohepatitis, discordance
between liver ﬁbrosis estimated by transient elastography
and biopsy occurred in one out of seven patients. Factors
which were associated with discordant results included
mild ﬁbrosis (F0–F2), higher BMI, ALT, and interquartile
range to median (IQR/M) liver stiffness ratio [64]. In
another study of 189 CHB patients, the BMI and lower
stages of ﬁbrosis (F0–F2) were identiﬁed as independent
predictors of signiﬁcant discordance between histology and
liver stiffness [65].
Limitations
Although transient elastography is a rapid and easy pro-
cedure, there are some limitations. To ensure the reliability
of liver stiffness results, strict adherence to quality criteria
should be followed. At least ten valid shots must be
obtained; the median value of the valid shots being repre-
sentative of the ﬁnal liver stiffness of the patient. In
examinations where zero valid measurement is obtained, it
is termed a failed scan. The success rate, which is deﬁned
as the number of valid shots divided by the total number of
shots, should also be C60%. Finally, the IQR/M ratio
should be B 30%. In those patients with less than ten valid
measurements, or a success rate of \60%, or an IQR/M
rate of[30%, the results would be considered as unreliable
or suboptimal. In an early study of 2,114 examinations, the
failure rate was 4.5%. The only factor associated with
failure was a BMI [28 [66]. In a more recent study of
13,369 examinations, the failure rate (as deﬁned by zero
valid measurements) was 3.1%, with BMI, operator expe-
rience, older age, and type 2 diabetes being independent
factors associated with scan failure. Unreliable scans were
noted in a further 15.8% of cases using the three criteria as
discussed previously, resulting in a total of 18.9% cases
with unreliable liver stiffness results [67]. In Asian
patients, the other common cause for failed scan includes
narrow intercostal spaces (seen mainly in young thin
females). In an intention-to-diagnose analysis, the high rate
of unreliable results may reduce the accuracy of transient
elastography.
Conclusions
Despite the absence of consensus guidelines, LSM using
transient elastography has become one of the most widely
used methods in the noninvasive assessment of liver ﬁbro-
sis. It is a rapid procedure with immediate results, and liver
stiffness has been shown to signiﬁcantly correlate with the
level of ﬁbrosis in CHB patients. It is a much welcomed
alternative to liver biopsy, and studies have shown that an
estimated 50–60% of patients with viral hepatitis can avoid
a liver biopsy by undergoing transient elastography [16, 68,
69]. Given the absence of adverse effects and the ease of the
procedure, there is a potential for population and disease
screening for the presence of signiﬁcant liver ﬁbrosis. In
addition to the assessment of liver ﬁbrosis, there is now
increasing evidence to show that LSM may have a longi-
tudinal role in assessing disease progression, therapeutic
response, and in predicting liver-related complications.
Further validation studies are required to conﬁrm the role of
transient elastography in these settings.
The increasing use of transient elastography is most
likely the consequence of patients and clinicians not
wanting or advocating liver biopsies, respectively. How-
ever, it should not be viewed as a replacement for other
tests of liver ﬁbrosis, as there are important limitations. The
major limitations of transient elastography include the
reduced diagnostic accuracy with lower ﬁbrosis stages (F0–
F2) and in patients with elevated ALT. Therefore, the
results should always be interpreted by a qualiﬁed clinician
according to the clinical context, taking into account the
patient demographics and laboratory parameters. Other
tests of liver ﬁbrosis, including biomarkers of ﬁbrosis,
should be considered as complementary tests to transient
elastography, and in situations where liver stiffness is
nondiagnostic or inconsistent with the clinical picture, a
liver biopsy is still recommended.
Finally, the focus now should include the development of
consensus statements on the use of transient elastography in
clinical practice, and to incorporate this technology into the
current CHB management guidelines. In addition, LSM in
assessing ﬁbrosis can be ﬁne-tuned, incorporating known
factors such as age, ALT, steatosis, and BMI into diagnostic
algorithms so that the accuracy can be further optimized.
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